Compare Abeona Therapeutics Inc (ABEO) vs Eaton Corporation plc (ETN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Eaton Corporation plc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Eaton Corporation plc trades at $398 (market cap $153.64B). The key difference: Eaton Corporation plc is far larger — about 411.6× Abeona Therapeutics Inc's market cap, and Eaton Corporation plc pays a 1.11% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ETN | |
|---|---|---|
Market Cap | $373.32M | $153.64B |
Sector | Health | Technology |
52-Week High | $7.23 | $435.78 |
52-Week Low | $4.17 | $315.82 |
Enterprise Value | $228.22M | $174.72B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Eaton (ETN) trades at $413.42, up 3.74% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 20.87% ROE and 13.99% net margin, though valuation ratios like a 40.45 P/E are elevated. Recent news highlights sustainability investments and AI infrastructure opportunities, while analyst consensus remains strongly positive with a $449.50 price target.
Outlook is supported by earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. The absence of sell ratings and institutional bullishness suggest upside potential, though investors should weigh growth against premium multiples in a volatile market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
